PDS Biotechnology Corp — Director's Dealing 2017

Sep 20, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2017-09-18

Reporting Person: Crane Rosemary A (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-09-18	Stock Option (Right To Purchase)	$9.43	A	30000	Acquired	2027-09-18	Common Stock (30000)	Direct

Footnotes

F1: One third of the option shares vest upon each of the first, second, and third anniversaries of the Transaction Date.